$0.02
0.00%
Nasdaq, Thu, Sep 26 2024
ISIN
US45258K1097
Symbol
IMPL
Sector
Industry

Impel NeuroPharma Inc. Stock price

$0.02
+0.00 0.00% 1M
-0.01 25.00% 6M
-0.11 87.85% YTD
-0.52 97.22% 1Y
-13.24 99.89% 3Y
-14.99 99.90% 5Y
-14.99 99.90% 10Y
Nasdaq, Closing price Thu, Sep 26 2024
+0.00 0.00%
ISIN
US45258K1097
Symbol
IMPL
Sector
Industry

Key metrics

Market capitalization $360.00k
Enterprise Value $110.42m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.26
P/S ratio (TTM) P/S ratio 0.02
P/B ratio (TTM) P/B ratio 0.00
Revenue growth (TTM) Revenue growth 155.29%
Revenue (TTM) Revenue $20.99m
EBIT (operating result TTM) EBIT $-70.11m
Free Cash Flow (TTM) Free Cash Flow $-81.98m
Cash position $4.74m
EPS (TTM) EPS $-3.13
Short interest 10.88%
Show more

Is Impel NeuroPharma Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Impel NeuroPharma Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Impel NeuroPharma Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Impel NeuroPharma Inc.:

Buy
100%

Financial data from Impel NeuroPharma Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '23
+/-
%
21 21
155% 155%
100%
- Direct Costs 12 12
102% 102%
57%
9.01 9.01
293% 293%
43%
- Selling and Administrative Expenses 73 73
3% 3%
347%
- Research and Development Expense 4.16 4.16
73% 73%
20%
-68 -68
23% 23%
-324%
- Depreciation and Amortization 2.03 2.03
68% 68%
10%
EBIT (Operating Income) EBIT -70 -70
21% 21%
-334%
Net Profit -74 -74
31% 31%
-354%

In millions USD.

Don't miss a Thing! We will send you all news about Impel NeuroPharma Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Impel NeuroPharma Inc. Stock News

Neutral
PRNewsWire
9 months ago
Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process SEATTLE , Dec. 19, 2023 /PRNewswire/ -- Impel Pharmaceuticals Inc. (OTCQX: IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medi...
Positive
InvestorPlace
about one year ago
Impel Pharmaceuticals (NASDAQ: IMPL ) stock is on the rise Friday after the company announced an amended credit agreement with Oaktree Fund Administration. This new credit agreement has Impel Pharmaceuticals obtaining a loan of $121.5 million from new and existing investors.
Negative
InvestorPlace
about one year ago
Impel Pharmaceuticals (NASDAQ: IMPL ) stock is falling on Wednesday after the biopharmaceutical company failed to file its earnings report on time. According to a filing with the Securities and Exchange Commission (SEC), several issues kept Impel Pharmaceuticals from filing in a timely manner.
More Impel NeuroPharma Inc. News

Company Profile

Impel NeuroPharma, Inc. operates as clinical stage biotechnology firm that develops medical devices. It offers intranasal drug treatments for central nervous system (CNS) disorders. The firm product candidates includes TRUDHESA, INP105, and INP107. The company was founded by Rodney J. Y. Ho, John D. Hoekman, and Michael P. Hite in 2008 and is headquartered in Seattle, WA.

Head office United States
CEO Leonard Paolillo
Founded 2008
Website impelpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today